NasdaqGM:XGNBiotechs
Exagen (XGN) Stock Jumps On Record Revenue But Profit Timing Remains Unclear
Exagen walked into this report as a small, loss making diagnostics stock that screens cheap on P/S and volatile on the chart. The market did not wait for the footnotes. The stock jumped about 38% to US$6.45 after earnings as investors reacted to a record quarter in autoimmune testing.
The headline is simple. Revenue reached US$19.9m in Q2, the highest in Exagen history, and adjusted EBITDA was almost at breakeven. Management also lifted full year 2026 revenue guidance to US$72m to US$75m,...